Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Establishment of a homozygous LMNA knock-out human induced pluripotent stem cell line using CRISPR/Cas9 system.

Park SH., Suh D., Kim H., Lee RR., Coscarella IL., Oh J.

Laboratory Study on Hip, published in Stem Cell Res (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Stem Cell Res (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
40706185
DOI
10.1016/j.scr.2025.103779

Abstract (original English)

The LMNA gene encodes lamin A/C, essential components of the nuclear envelope that play crucial roles in maintaining nuclear architecture, mechanotransduction, and gene regulation. LMNA mutations are linked to laminopathies, affecting multiple organ systems, including muscle, adipose tissue, and the cardiovascular system. To investigate LMNA-related disorders, we generated a human-induced pluripotent stem cell (hiPSC) line with a homozygous LMNA frameshift mutation (c.351_352insA) using CRISPR/Cas9 genome editing. The edited hiPSCs retained normal colony morphology and expressed key pluripotency markers. This LMNA knockout hiPSC line provides a valuable model for studying lamin A/C functions in nuclear integrity, cellular homeostasis, and disease pathogenesis.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansInduced Pluripotent Stem CellsLamin Type ACRISPR-Cas SystemsHomozygoteCell LineGene EditingGene Knockout TechniquesFrameshift Mutation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research